Altimmune Deferred Long Term Liab from 2010 to 2024
| ALT Stock | USD 8.25 0.07 0.86% |
Deferred Long Term Liabilities | First Reported 2011-06-30 | Previous Quarter 58.5 K | Current Value 58.5 K | Quarterly Volatility 2.4 M |
Check Altimmune financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Altimmune's main balance sheet or income statement drivers, such as Interest Expense of 33.2 K, Selling General Administrative of 13.5 M or Total Revenue of 404.7 K, as well as many indicators such as Price To Sales Ratio of 1.5 K, Dividend Yield of 0.0 or PTB Ratio of 3.24. Altimmune financial statements analysis is a perfect complement when working with Altimmune Valuation or Volatility modules.
Altimmune | Deferred Long Term Liab |
Latest Altimmune's Deferred Long Term Liab Growth Pattern
Below is the plot of the Deferred Long Term Liab of Altimmune over the last few years. It is liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue. Altimmune's Deferred Long Term Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Altimmune's overall financial position and show how it may be relating to other accounts over time.
| Deferred Long Term Liab | 10 Years Trend |
|
Deferred Long Term Liab |
| Timeline |
Altimmune Deferred Long Term Liab Regression Statistics
| Arithmetic Mean | 1,009,330 | |
| Geometric Mean | 0.00 | |
| Coefficient Of Variation | 159.08 | |
| Mean Deviation | 1,139,821 | |
| Median | 67,275 | |
| Standard Deviation | 1,605,657 | |
| Sample Variance | 2.6T | |
| Range | 5.9M | |
| R-Value | (0.45) | |
| Mean Square Error | 2.2T | |
| R-Squared | 0.20 | |
| Significance | 0.1 | |
| Slope | (159,813) | |
| Total Sum of Squares | 36.1T |
Altimmune Deferred Long Term Liab History
About Altimmune Financial Statements
Altimmune shareholders use historical fundamental indicators, such as Deferred Long Term Liab, to determine how well the company is positioned to perform in the future. Although Altimmune investors may analyze each financial statement separately, they are all interrelated. The changes in Altimmune's assets and liabilities, for example, are also reflected in the revenues and expenses on on Altimmune's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Deferred Long Term Liabilities | 67.3 K | 63.9 K |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Altimmune Stock Analysis
When running Altimmune's price analysis, check to measure Altimmune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Altimmune is operating at the current time. Most of Altimmune's value examination focuses on studying past and present price action to predict the probability of Altimmune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Altimmune's price. Additionally, you may evaluate how the addition of Altimmune to your portfolios can decrease your overall portfolio volatility.